Home Cart Sign in  
Chemical Structure| 960203-27-4 Chemical Structure| 960203-27-4

Structure of Vortioxetine HBr
CAS No.: 960203-27-4

Chemical Structure| 960203-27-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vortioxetine HCl, a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.

Synonyms: Lu AA21004 hydrobromide; Vortioxetine hydrobromide; Vortioxetine (hydrobromide)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vortioxetine HBr

CAS No. :960203-27-4
Formula : C18H23BrN2S
M.W : 379.36
SMILES Code : CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(C)=C1.[H]Br
Synonyms :
Lu AA21004 hydrobromide; Vortioxetine hydrobromide; Vortioxetine (hydrobromide)
MDL No. :MFCD22383961
InChI Key :VNGRUFUIHGGOOM-UHFFFAOYSA-N
Pubchem ID :56843850

Safety of Vortioxetine HBr

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360-H373-H410
Precautionary Statements:P201-P202-P260-P273-P280-P308+P313-P391-P405-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Vortioxetine HBr

GPCR

Isoform Comparison

Biological Activity

Description
Vortioxetine is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with Ki values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. Vortioxetine exhibits antagonist activity at 5-HT3A and 5-HT7 receptors, is a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and strongly inhibits SERT[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03555136 - Recruiting June 30, 2020 United States, Missouri ... More >> US 0039 Mattingly Recruiting Saint Charles, Missouri, United States, 63304 Contact: Email Contact via H. Lundbeck A/S Less <<
NCT02386488 Pharmacokinetics Phase 1 Completed - China ... More >> CB801 Chengdu, China Less <<
NCT02969876 Depressive Disorder ... More >> Major Depression Depression Depression, Unipolar Less << Phase 4 Recruiting November 2018 United States, Massachusetts ... More >> the Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Kyle Palmstrom, B.S.    617-724-9458    kpalmstrom@mgh.harvard.edu    Principal Investigator: Andrew Nierenberg, M.D. Less <<
NCT02327013 - Completed - -
NCT03187093 Major Depressive Disorder Phase 4 Recruiting September 2018 Ukraine ... More >> State Institution "Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine" Recruiting Zaporizhzhia, Ukraine, 69096 Contact: Alexandra Troyan, MD    +380673287519    troian@zmapo.edu.ua Less <<
NCT02871297 Depressive Disorder, Major Phase 3 Enrolling by invitation September 2019 -
NCT02072278 Healthy Men Phase 1 Completed - France ... More >> FR801 Rennes, France, 35000 Less <<
NCT02272517 Major Depressive Disorder Phase 3 Completed - Finland ... More >> FI005 Helsinki, Finland FI001 Kuopio, Finland FI006 Kupio, Finland FI007 Tampere, Finland FI004 Turku, Finland Germany DE005 Bochum, Germany DE004 Mittweida, Germany Serbia RS002 Belgrade, Serbia RS003 Belgrade, Serbia RS004 Belgrade, Serbia RS005 Belgrade, Serbia RS001 Kragujevac, Serbia Slovakia SK004 Bratislava, Slovakia SK001 Hronovce, Slovakia SK003 Levice, Slovakia SK002 Rimavska Sobota, Slovakia Less <<
NCT02327013 Attention Deficit Hyperactivit... More >>y Disorder Less << Phase 2 Completed - United States, California ... More >> US015 Beverly Hills, California, United States US002 Garden Grove, California, United States US004 National City, California, United States United States, Florida US013 Bradenton, Florida, United States US006 Gainesville, Florida, United States United States, Georgia US010 Alpharetta, Georgia, United States United States, Illinois US014 Libertyville, Illinois, United States United States, Maryland US011 Baltimore, Maryland, United States United States, Massachusetts US009 Boston, Massachusetts, United States United States, Nevada US016 Las Vegas, Nevada, United States United States, New York US005 New York, New York, United States US008 New York, New York, United States United States, Texas US001 Austin, Texas, United States United States, Virginia US007 Herndon, Virginia, United States United States, Washington US003 Bellevue, Washington, United States Less <<
NCT02709746 Depressive Disorder, Major Phase 3 Recruiting April 2019 -
NCT03108625 Depressive Disorder, Major Phase 3 Active, not recruiting May 2020 -
NCT02279966 Major Depressive Disorder Phase 3 Completed - Estonia ... More >> EE001 Tallinn, Estonia EE002 Tallinn, Estonia EE004 Voru, Estonia Finland FI002 Helsinki, Finland FI003 Helsinki, Finland FI001 Kuopio, Finland FI008 Oulu, Finland FI007 Tampere, Finland Germany DE002 Berlin, Germany DE001 Bielefeld, Germany DE003 Frankfurt, Germany DE007 Frankfurt, Germany DE008 Schwerin, Germany Lithuania LT002 Kaunas, Lithuania LT006 Palanga, Lithuania LT003 Silute, Lithuania LT001 Vilnius, Lithuania LT005 Vilnius, Lithuania Less <<
NCT02709655 Depressive Disorder, Major Phase 3 Recruiting May 2021 -
NCT02454426 Major Depressive Disorder ... More >> Coronary Artery Disease Less << Early Phase 1 Withdrawn(PI left institution) - United States, Pennsylvania ... More >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT02357797 Schizophrenia ... More >> Negative Symptoms Less << Phase 4 Recruiting March 2020 United States, New York ... More >> The Zucker Hillside Hospital Recruiting Glen Oaks, New York, United States, 11004 Contact: Christoph U Correll, MD    718-470-4812    ccorrell@nshs.edu Less <<
NCT02528409 Binge Eating Disorder Phase 2 Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT03598868 Bipolar Disorder Depression Phase 2 Recruiting September 25, 2021 Korea, Republic of ... More >> Inha University Hospital Not yet recruiting Incheon, Korea, Republic of Contact: Hyeyoung Kim, MD          Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Yong Min Ahn, MD. PHD Less <<
NCT02294305 Social Anxiety Disorder ... More >> Major Depressive Disorder Less << Phase 4 Unknown November 2016 United States, New York ... More >> The Medical Research Network, LLC New York, New York, United States, 10128 Less <<
NCT02170220 Severe Hepatic Impairment Phase 1 Completed - United States, Florida ... More >> University of Miami Miami, Florida, United States Less <<
NCT02279953 Major Depressive Disorder Phase 3 Completed - Estonia ... More >> EE001 Tallinn, Estonia EE002 Tallinn, Estonia Finland FI002 Helsinki, Finland FI003 Helsinki, Finland FI005 Helsinki, Finland FI001 Kuopio, Finland FI006 Kupio, Finland FI004 Turku, Finland Germany DE002 Berlin, Germany DE001 Bielefeld, Germany DE005 Bochum, Germany DE003 Frankfurt, Germany DE004 Mittweida, Germany Serbia RS002 Belgrade, Serbia RS001 Kragujevac, Serbia Slovakia SK003 Levice, Slovakia SK002 Rimavska Sobota, Slovakia Less <<
NCT02170220 - Completed - -
NCT02972632 Major Depressive Disorder Phase 4 Completed - United States, California ... More >> ATP Clinical Research, Inc. Costa Mesa, California, United States, 92626 ProScience Research Group Culver City, California, United States, 90230 Behavioral Research Specialists, LLC Glendale, California, United States, 91206 Pacific Research Partners Oakland, California, United States, 94607 Excell Research Oceanside, California, United States, 92056 Anderson Clinical Research Redlands, California, United States, 92374 University Medical Group Upland, California, United States, 91207 United States, Colorado MCB Clinical Research Centers, LLC Colorado Springs, Colorado, United States, 80910 United States, Florida Suncoast Clinical Research Inc. New Port Richey, Florida, United States, 34652 Behavioral Clinical Research , Inc North Miami, Florida, United States, 33162 Compass Research Main Orlando, Florida, United States, 32806 University of South Florida Tampa, Florida, United States, 33613 United States, Illinois Great Lakes Clinical Trials Chicago, Illinois, United States, 60640 Baber Research Group Naperville, Illinois, United States, 60563 United States, Indiana Deaconess Clinic Evansville, Indiana, United States, 47713-1227 United States, Massachusetts Novex Clinical Research, LLC New Bedford, Massachusetts, United States, 2740 Coastal Research Associates, Inc. South Weymouth, Massachusetts, United States, 2190 United States, Michigan University of Michigan, Ann Arbor Ann Arbor, Michigan, United States, 48109 United States, New York Columbia University Medical Center New York, New York, United States, 10023 United States, Ohio Dayton Clinical Research Dayton, Ohio, United States, 45406 United States, Pennsylvania Green & Seidner Family Practice Associates Lansdale, Pennsylvania, United States, 19446 United States, Texas Relaro Medical Trials Dallas, Texas, United States, 75243 Red Oak Psychiatry Associates, PA Houston, Texas, United States, 77090 Radiant Research, Inc. San Antonio, Texas, United States, 78229 Family Psychiatry of The Woodlands The Woodlands, Texas, United States, 77381 Less <<
NCT01491035 Depressive Disorder ... More >> Anxiety Disorder Less << Phase 2 Completed - United States, District of Col... More >>umbia US003 Washington, District of Columbia, United States, 20010 United States, Kansas US004 Wichita, Kansas, United States, 67214 United States, Ohio US002 Cincinnatti, Ohio, United States, 45219 US001 Cleveland, Ohio, United States, 44106 Germany DE002 Berlin, Germany, 10249 DE001 Mainz, Germany, 55122 DE003 Ulm, Germany, 89075 Less <<
NCT01491035 - Completed - -
NCT03766867 Major Depressive Disorder Phase 2 Recruiting May 27, 2019 Estonia ... More >> Tartu University Hospital (EE2002) Recruiting Tartu, Estonia Latvia Riga Centre of Psychiatry and Narcology (LV3002) Not yet recruiting Riga, Latvia Less <<
NCT00635219 Major Depressive Disorder Phase 3 Completed - -
NCT02371980 Major Depressive Disorder Phase 4 Active, not recruiting May 1, 2019 -
NCT00839423 - Completed - -
NCT00672620 Major Depressive Disorder Phase 3 Completed - -
NCT00839423 Major Depressive Disorder Phase 2 Completed - -
NCT00672620 - Completed - -
NCT01422213 Major Depressive Disorder Phase 3 Completed - -
NCT00730691 Generalized Anxiety Disorder Phase 3 Completed - -
NCT00730691 - Completed - -
NCT00635219 - Completed - -
NCT00811252 Major Depressive Disorder Phase 3 Completed - -
NCT00811252 - Completed - -
NCT01153009 Depressive Disorder, Major Phase 3 Completed - -
NCT01422213 - Completed - -
NCT01140906 Major Depressive Disorder Phase 3 Completed - -
NCT01153009 - Completed - -
NCT00744627 Generalized Anxiety Disorder Phase 3 Completed - -
NCT01140906 - Completed - -
NCT00734071 Generalized Anxiety Disorder Phase 3 Completed - -
NCT00744627 - Completed - -
NCT00734071 - Completed - -
NCT00731120 - Completed - -
NCT00735709 Major Depressive Disorder Phase 3 Completed - -
NCT00707980 Major Depressive Disorder Phase 3 Completed - -
NCT00735709 - Completed - -
NCT01163266 Depressive Disorder, Major Phase 3 Completed - -
NCT00707980 - Completed - -
NCT01179516 Depressive Disorder, Major Phase 3 Completed - -
NCT01163266 - Completed - -
NCT01255787 Depressive Disorder, Major Phase 2 Phase 3 Completed - -
NCT01255787 - Completed - -
NCT00731120 Generalized Anxiety Disorder Phase 3 Completed - -
NCT01299805 - Completed - -
NCT01488071 Major Depressive Disorder Phase 3 Completed - -
NCT01152996 - Completed - -
NCT01152996 Depressive Disorder, Major Phase 3 Completed - -
NCT01488071 - Completed - -
NCT01299805 Healthy Phase 1 Completed - United States, California ... More >> Glendale, California, United States Less <<
NCT00596817 Major Depressive Disorder Phase 3 Completed - -
NCT01364649 Treatment Outcome Phase 3 Completed - -
NCT00596817 - Completed - -
NCT01607125 Depression Phase 1 Completed - United Kingdom ... More >> GB001 Headington, United Kingdom, OX3 7JX Less <<
NCT01364649 - Completed - -
NCT01179516 - Completed - -
NCT00694304 Major Depressive Disorder Phase 3 Completed - -
NCT00761306 Major Depressive Disorder Phase 2 Completed - -
NCT00694304 - Completed - -
NCT00761306 - Completed - -
NCT01355081 - Completed - -
NCT01323478 Major Depressive Disorder Phase 3 Completed - -
NCT00788034 Generalized Anxiety Disorder Phase 3 Completed - -
NCT00672958 Major Depressive Disorder Phase 3 Completed - -
NCT01571453 Major Depressive Disorder Phase 3 Completed - -
NCT01355081 Major Depressive Disorder Phase 3 Completed - Japan ... More >> Inzai-shi, Chiba, Japan Noda-City, Chiba, Japan Fukuoka-city, Fukuoka, Japan Kitakyushu-shi, Fukuoka, Japan Annaka-shi, Gunma, Japan Fujioka-shi, Gunma, Japan Takasaki-shi, Gunma, Japan Hatsukaichi-shi, Hiroshima, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-Shi, Hokkaido, Japan Amagasaki-shi, Hyogo, Japan Kobe-shi, Hyogo, Japan Fujisawa-shi, Kanagawa, Japan Kawasaki-shi, Kanagawa, Japan Sagamihara-shi, Kanagawa, Japan Yokohama-shi, Kanagawa, Japan Osaka-shi, Kita-ku, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Kurashiki-shi, Okayama, Japan Osaka-shi, Osaka, Japan Fukaya-shi, Saitama, Japan Saitama-city, Saitama, Japan Utsunomiya-shi, Tochigi, Japan Anan-shi, Tokushima, Japan Tokushisma-shi, Tokushima, Japan Hachioji-shi, Tokyo, Japan Katsushika-ku, Tokyo, Japan Musashino-shi, Tokyo, Japan Nanyo-shi, Yamagata, Japan Ibaraki, Japan Tokyo, Japan Less <<
NCT01571453 - Completed - -
NCT01676571 Healthy Phase 1 Completed - China ... More >> CN001 Tianjin, China, 300457 Less <<
NCT01323478 - Completed - -
NCT01395147 Major Depressive Disorder Phase 3 Completed - Japan ... More >> Inzai-shi, Chiba, Japan Noda-City, Chiba, Japan Fukuoka-city, Fukuoka, Japan Kitakyushu-shi, Fukuoka, Japan Annaka-shi, Gunma, Japan Fujioka-shi, Gunma, Japan Takasaki-shi, Gunma, Japan Hatsukaichi-shi, Hiroshima, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-Shi, Hokkaido, Japan Amagasaki-shi, Hyogo, Japan Kobe-shi, Hyogo, Japan Fujisawa-shi, Kanagawa, Japan Kawasaki-shi, Kanagawa, Japan Sagamihara-shi, Kanagawa, Japan Yokohama-shi, Kanagawa, Japan Osaka-shi, Kita-ku, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Kurashiki-shi, Okayama, Japan Osaka-shi, Osaka, Japan Fukaya-shi, Saitama, Japan Saitama-city, Saitama, Japan Utsunomiya-shi, Tochigi, Japan Anan-shi, Tokushima, Japan Tokushisma-shi, Tokushima, Japan Hachioji-shi, Tokyo, Japan Katsushika-ku, Tokyo, Japan Musashino-shi, Tokyo, Japan Nanyo-shi, Yamagata, Japan Ibaraki, Japan Tokyo, Japan Less <<
NCT00672958 - Completed - -
NCT01564862 Depressive Disorder, Major Phase 2 Completed - -
NCT03437564 Healthy Adult Participants Phase 1 Completed - Japan ... More >> Nishi Kumamoto Hospital Kumamoto, Japan Less <<
NCT02389816 Major Depressive Disorder Phase 3 Completed - Japan ... More >> Nagoya, Aichi, Japan Noda, Chiba, Japan Ruzan, Chiba, Japan Iizuka, Fukuoka, Japan Kitakyushu, Fukuoka, Japan Kurume, Fukuoka, Japan Kouriyama, Fukushima, Japan Shirakawa, Fukushima, Japan Sapporo, Hokkaido, Japan Ashiya, Hyogo, Japan Kanazawa, Ishikawa, Japan Kawasaki, Kanagawa, Japan Yokohama, Kanagawa, Japan Yokosuka, Kanagawa, Japan Kurashiki, Okayama, Japan Kadoma, Osaka, Japan Kita-ku, Osaka, Japan Osakasayama, Osaka, Japan Sakai, Osaka, Japan Karatsu, Saga, Japan Kawagoe, Saitama, Japan Kusatsu, Shiga, Japan Anan, Tokushima, Japan Arakawa-ku, Tokyo, Japan Chiyoda-ku, Tokyo, Japan Hachiouji, Tokyo, Japan Itabashi-ku, Tokyo, Japan Katsushika-ku, Tokyo, Japan Koutou-ku, Tokyo, Japan Meguro-ku, Tokyo, Japan Minato-ku, Tokyo, Japan Mitaka, Tokyo, Japan Musashino, Tokyo, Japan Nakano-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shibuya-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Suginami-ku, Tokyo, Japan Taito-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan Kofu, Yamanashi, Japan Fukuoka, Japan Hiroshima, Japan Kumamoto, Japan Okayama, Japan Saitama, Japan Less <<
NCT01564862 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.64mL

0.53mL

0.26mL

13.18mL

2.64mL

1.32mL

26.36mL

5.27mL

2.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories